Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
2015
2014
EMA policy on clinical data publication a step ahead, but falls short of true potential
Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry
Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA
Hoping for "harmony" on global antibiotic resistance strategy
Week in review: Outcomes from WHA67
Progress on access to medicines at WHA67, but WHO funding sorely needed
World Health Assembly: HAI and ARC intervention on antimicrobial resistance, including antibiotic resistance
World Health Assembly 67: HAI and KEI intervention on the Consultative Expert Working Group on Research and Development
World Health Assembly 67: HAI intervention on access to essential medicines
World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors
Tamiflu review shows desperate need for full clinical trials data transparency
New materials help assess medicines policies and interventions
A new (and improved) model to regulate pharmaceutical promotion
Enhancing accountability in the medicines market: The Medicines Transparency Alliance
Leaks and Lies: Pharma’s strategy to derail South Africa’s intellectual property reforms exposed
Selected R&D demonstration projects disappointing: Innovation models with new incentive mechanisms needed
2013
Bracing for another delay – open innovation at the WHO?
2011
DG Trade State of Play reveals EU's ambitions for IP protection in FTAs
Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN
Conflicts of Interest and the Future of Financing for WHO.
Foundations: Conlicts of interests and Democracy issues
2010